TALC
Clinical safety rating
cautionComprehensive clinical and safety monograph for TALC (TALC).
Talc (magnesium silicate) induces pleural fibrosis and adhesion by causing an inflammatory response and fibroblast proliferation, leading to symphysis of the pleural layers.
| Metabolism | Not metabolized; inert substance. Cleared by lymphatic drainage and phagocytosis by macrophages. |
| Excretion | Talc is not absorbed systemically; elimination is primarily via fecal excretion of the unabsorbed material. In cases of pleural administration, talc particles are cleared by lymphatic drainage and may be phagocytized by macrophages; no significant renal or biliary excretion occurs. |
| Half-life | Not applicable; talc is a non-absorbable material. No systemic half-life exists; local persistence in pleural space can be months to years. |
| Protein binding | Not applicable; talc does not bind to plasma proteins as it is not systemically absorbed. |
| Volume of Distribution | Not applicable; talc remains at site of administration (pleural space, lungs) or in GI tract; no systemic distribution. |
| Bioavailability | Oral: negligible (<0.1%); inhalation: minimal systemic absorption; intrapleural: not systemically available. |
| Onset of Action | Intrapleural administration: 24-72 hours for pleurodesis effect; inhalation: immediate mechanical irritation, with clinical effects (cough, dyspnea) occurring within minutes to hours. |
| Duration of Action | Pleurodesis: weeks to permanent; inhaled talc effects may last hours to days, residual pleural fibrosis permanent. |
| Molecular Weight | 379.28 |
Intrapleural administration: 5 g mixed with 250 mL normal saline instilled via chest tube, followed by clamping for 1 hour then drainage.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required; talc is not significantly renally eliminated. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Not established; safety and efficacy in children have not been determined. |
| Geriatric use | No specific dose adjustment; use with caution due to potential comorbidities and reduced pulmonary reserve. |
| 1st trimester | Talc is generally considered safe in the first trimester when used topically or orally for minor indications. Systemic absorption is minimal, and there are no reports of teratogenicity. |
| 2nd trimester | Similar safety profile as first trimester. No known fetal risks from topical or limited oral exposure. |
| 3rd trimester | Use caution near term due to theoretical risk of aspiration if used in vaginal formulations, but no evidence of harm. |
Clinical note
Comprehensive clinical and safety monograph for TALC (TALC).
| Placental transfer | Talc particles are minimally absorbed; significant transfer is unlikely. |
| Breastfeeding | Talc is not absorbed systemically in significant amounts when used topically or orally, so it is considered compatible with breastfeeding. Avoid direct application to the breast to prevent infant ingestion. |
| Lactation Rating | L1 (Compatible) |
| Teratogenic Risk | No known teratogenic risk; talc is not absorbed systemically when applied topically or used perineally. No fetal harm reported in any trimester. |
| Fetal Monitoring | No specific monitoring required due to lack of systemic absorption. |
| Fertility Effects | No known effects on fertility from topical use. Intraperitoneal talc (as in pleurodesis) may cause pelvic adhesions reducing fertility in women. |
■ FDA Black Box Warning
None
| Serious Effects |
Do not use in patients with known hypersensitivity to talc.Avoid intravaginal use in women with history of pelvic inflammatory disease or ovarian cancer.Do not use in body cavities unless specifically indicated for pleurodesis.
| Precautions | Risk of acute respiratory distress syndrome (ARDS) and pneumonitis due to systemic absorption, Hypersensitivity reactions including anaphylaxis, Fever and chest pain common post-procedure, Do not use in patients with extensive pleural fibrosis or trapped lung |
| Food/Dietary | No known food interactions with intrapleural talc administration. |
| Clinical Pearls | Talc is used for pleurodesis in malignant pleural effusions. Administer as intrapleural slurry via chest tube; premedicate with lidocaine to reduce pain. Monitor for fever, chest pain, and respiratory distress. Contraindicated in patients with known talc sensitivity or active infection. |
| Patient Advice | Talc is used to prevent fluid buildup in the chest cavity by causing the lung to stick to the chest wall. · You may experience chest pain, fever, or shortness of breath after the procedure. · Report any worsening pain, difficulty breathing, or signs of infection such as chills or fever. · This procedure is not a cure for the underlying cancer but helps manage symptoms. |
Loading safety data…